This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | MicrobiomeTrials
← Back to trials NCT05083481
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors TERMINATED PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2021-10-19Est. Completion: 2026-05-11
Enrollment target: 226 participantsLocations Providence Medical Foundation, Fullerton, California, United States California Research Institute, Los Angeles, California, United States USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States Florida Cancer Specialist & Research Institute Sarasota, Sarasota, Florida, United States University of Chicago, Chicago, Illinois, United States University of Kentucky Medical Center MCC-CRO, Lexington, Kentucky, United States Nebraska Methodist Hospital, Omaha, Nebraska, United States University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States SCRI Oncology Partners, Nashville, Tennessee, United States Mary Crowley Research Center, Dallas, Texas, United States University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), Hangzhou, Zhejiang, China Beijing Cancer Hospital, Beijing, China Shanghai East Hospital, Shanghai, China Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China FR33007, Besançon, France Site FR33002, Bordeaux, France FR33008, Paris, France FR33005, Saint-Herblain, France FR33009, Toulouse, France National Cancer Center Hospital, Chuo-ku, Tokyo, Japan Cancer Institute Hospital Of JFCR, Koto-ku, Tokyo, Japan Puerto Rico Medical Center, Río Piedras, Puerto Rico Site ES34005, A Coruña, Barcelona, Spain Site ES34002, Madrid, Spain ES34008, Málaga, Spain Site ES34007, Málaga, Spain Site ES34006, Pozuelo de Alarcón, Spain Other microbiome trials you might be interested in EGFR Overexpression Locally Advanced Solid Tumor Metastatic Solid Tumor
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Ad…
Seoul, South Korea Est. completion Jun 2027
Recurrent Melanoma (Skin) Metastatic Melanoma Melanoma Stage IV Melanoma Stage III
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therape…
Orange, United States Est. completion Dec 31, 2027
Breast Cancer Solid Tumor
This is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of…
Boston, United States Est. completion Dec 31, 2026